To combat COVID-19, Moderna launched a Phase 1 study consisting of 45 participants in an effort to create a vaccine on an expedited timeline. March 16th was the start of the Phase 1 testing. The initial group of 45 people were divided into groups of 15 individuals. Each grouping received 2 doses of treatment, but each group received a different dosage of the proposed vaccine (25, 100, or 250 microgram dosages). The subjects who received both doses, showed higher levels of virus-defeating antibodies when compared to individuals who had recovered from the coronavirus. The majority of participants who received both dosages did report adverse reactions, as to be expected during the trials.
The narrative today is that we are facing a global pandemic due to the coronavirus outbreak. It's absolutely crushing equity and oil markets with the Dow Jones Industrial Average down 980 points and WTI crude oil down $2.75/barrel – and it could get worse.
With global chatter circling around the latest mass scale respiratory ailment, the coronavirus, there is global glut of petroleum fuels. Like SARS, in 2003, the coronavirus is thought to spread through respiratory droplets being transmitted form one person to another (i.e., sneeze or cough). With the potential for person to person transmission being so high, major travel has been hindered by the fear of either spreading or acquiring the new virus. With more than 17,000 cases already and growing, there is now concerns on how to handle the temporary glut of fuels in the market.